
#### Medicare PLUS Blue™ Group PPO Prescription Blue™ Group PDP







Blue Cross Blue Shield of Michigan is a nonprofit corporation and independent licensee of the Blue Cross and Blue Shield Association.

#### **Attention Blue Cross Blue Shield of Michigan members:**

This is a list of changes made to the Medicare Plus Blue Group PPO and Prescription Blue Group PDP Group Comprehensive and Group Enhanced Comprehensive formularies since their initial release in October 2023

Blue Cross may add or remove drugs from our formulary during the year. If we make any of the following changes, we'll notify you at least 30 days before the effective date:

- Remove drugs from our formulary
- Add prior authorization, quantity limits or step therapy to a drug
- Move a drug to a higher cost-sharing tier

Some formulary changes don't require advance notice but will be posted on this <u>link</u>. If your physician prescribes a drug that isn't on our formulary, isn't a preferred drug or is subject to additional utilization requirements, you can ask us to make a coverage exception. You or your physician can initiate an exception request. While the use of a form isn't always required, it's available on the Blue Cross website at <a href="https://www.bcbsm.com/medicare">www.bcbsm.com/medicare</a>.

We'll make coverage determinations for standard and urgent requests within 72 and 24 hours, respectively. If Blue Cross denies coverage for your prescription drugs, we'll explain our decision. You always have the right to appeal and ask us to review a claim denial. For more detailed information about your Blue Cross prescription drug coverage, review your Medicare Plus Blue or Prescription Blue *Formulary* or *Evidence of Coverage*.

If you have questions about the Blue Cross drug formulary, call Customer Service at **1-866-684-8216** from 8:30 a.m. to 5 p.m. Eastern time Monday through Friday. From October 1 through March 31, hours are from 8 a.m. to 9 p.m. Eastern time, seven days a week. TTY users call 711.

(Updated 5/1/2024)

# Changes made to the drugs in Medicare Plus Blue Group PPO and Prescription Blue Group PDP Group Comprehensive and Group Enhanced Comprehensive Formularies (additions, deletions, changes in coverage)

| Effective<br>Date | Brand Name   | Generic Name                             | Type of<br>Change        | Reason for<br>Change                | Notes                                  |
|-------------------|--|--|--------------------------|-------------------------------------|--|
| 5/1/2024          | FLUTICASONE PROPIONATE HFA<br>44MCG/ACT, 110MCG/ACT, 220MCG/ACT<br>INHALATION    |  | Addition to<br>Formulary | General<br>Formulary<br>Maintenance | Drug is on Tier 3 with Quantity Limits |
| 5/1/2024          | FLUTICASONE PROPIONATE DISKUS<br>50MCG/ACT, 100MCG/ACT, 250MCG/ACT<br>INHALATION |  | Addition to<br>Formulary | General<br>Formulary<br>Maintenance | Drug is on Tier 3 with Quantity Limits |
| 5/1/2024          |  | heather 0.35mg oral tablet               | Addition to<br>Formulary | General<br>Formulary<br>Maintenance | Drug is on Tier 2                      |
| 5/1/2024          |  | indomethacin 25mg/5ml oral<br>suspension | Addition to<br>Formulary | General<br>Formulary<br>Maintenance | Drug is on Tier 4                      |
| 5/1/2024          | IXCHIQ INJECTION   |  | Addition to<br>Formulary | General<br>Formulary<br>Maintenance | Drug is on Tier 3                      |

(Updated 5/1/2024)

# Changes made to the drugs in Medicare Plus Blue Group PPO and Prescription Blue Group PDP Group Comprehensive and Group Enhanced Comprehensive Formularies (additions, deletions, changes in coverage)

| Effective<br>Date | Brand Name   | Generic Name                   | Type of<br>Change        | Reason for<br>Change                | Notes   |
|-------------------|--|--------------------------------|--------------------------|-------------------------------------|---|
| 5/1/2024          | JOENJA 70MG ORAL TABLET                                  |                                | Addition to<br>Formulary | General<br>Formulary<br>Maintenance | Drug is on Tier 5<br>with Prior<br>Authorization &<br>Quantity Limits |
| 5/1/2024          |  | mifepristone 300mg oral tablet | Addition to<br>Formulary | General<br>Formulary<br>Maintenance | Drug is on Tier 5<br>with Prior<br>Authorization                      |
| 5/1/2024          | MOTPOLY XR 150MG, 200MG EXTENDED<br>RELEASE ORAL CAPSULE |                                | Addition to<br>Formulary | General<br>Formulary<br>Maintenance | Drug is on Tier 5<br>with Prior<br>Authorization &<br>Quantity Limits |
| 5/1/2024          | RIVFLOZA 80MG/0.5ML INJECTION                            |                                | Addition to<br>Formulary | General<br>Formulary<br>Maintenance | Drug is on Tier 5<br>with Prior<br>Authorization &<br>Quantity Limits |

(Updated 5/1/2024)

# Changes made to the drugs in Medicare Plus Blue Group PPO and Prescription Blue Group PDP Group Comprehensive and Group Enhanced Comprehensive Formularies (additions, deletions, changes in coverage)

| Effective<br>Date | Brand Name  | Generic Name | Type of<br>Change        | Reason for<br>Change                | Notes   |
|-------------------|---|--------------|--------------------------|-------------------------------------|---|
| 5/1/2024          | RIVFLOZA 128MG/0.8ML, 160MG/ML<br>PREFILLED SYRINGE     |              | Addition to<br>Formulary | General<br>Formulary<br>Maintenance | Drug is on Tier 5<br>with Prior<br>Authorization &<br>Quantity Limits |
| 5/1/2024          | ROZLYTREK 50MG ORAL PELLET                              |              | Addition to<br>Formulary | General<br>Formulary<br>Maintenance | Drug is on Tier 5<br>with Prior<br>Authorization &<br>Quantity Limits |
| 5/1/2024          | TERIPARATIDE 620MCG/2.48ML<br>INJECTION                 |              | Addition to<br>Formulary | General<br>Formulary<br>Maintenance | Drug is on Tier 5<br>with Prior<br>Authorization &<br>Quantity Limits |
| 5/1/2024          | TRIENTINE HYDROCHLORIDE 500MG<br>ORAL CAPSULE           |              | Addition to<br>Formulary | General<br>Formulary<br>Maintenance | Drug is on Tier 5   |
| 5/1/2024          | XOLAIR 75MG/0.5ML, 150MG/ML,<br>300MG/2ML AUTO INJECTOR |              | Addition to<br>Formulary | General<br>Formulary<br>Maintenance | Drug is on Tier 5<br>with Prior<br>Authorization                      |

(Updated 5/1/2024)

# Changes made to the drugs in Medicare Plus Blue Group PPO and Prescription Blue Group PDP Group Comprehensive and Group Enhanced Comprehensive Formularies (additions, deletions, changes in coverage)

| Effective<br>Date | Brand Name                         | Generic Name | Type of<br>Change        | Reason for<br>Change                | Notes  |
|-------------------|------------------------------------|--------------|--------------------------|-------------------------------------|--|
| 5/1/2024          | XOLAIR 300MG/2ML PREFILLED SYRINGE |              | Addition to<br>Formulary | General<br>Formulary<br>Maintenance | Drug is on Tier 5<br>with Prior<br>Authorization |

(Updated 5/1/2024)

# Changes made to the drugs in Medicare Plus Blue Group PPO and Prescription Blue Group PDP Group Comprehensive and Group Enhanced Comprehensive Formularies (additions, deletions, changes in coverage)

| Effective<br>Date | Brand Name                       | Generic Name                               | Type of<br>Change        | Reason for<br>Change                | Notes   |
|-------------------|----------------------------------|--|--------------------------|-------------------------------------|---|
| 4/1/2024          | BOSULIF 50MG, 100MG ORAL CAPSULE |  | Addition to<br>Formulary | General<br>Formulary<br>Maintenance | Drug is on Tier 5<br>with Prior<br>Authorization &<br>Quantity Limits |
| 4/1/2024          |                                  | bromfenac sodium 0.07% ophthalmic solution | Addition to<br>Formulary | General<br>Formulary<br>Maintenance | Drug is on tier 4   |
| 4/1/2024          | IWILFIN 192MG ORAL TABLET        |  | Addition to<br>Formulary | General<br>Formulary<br>Maintenance | Drug is on Tier 5<br>with Prior<br>Authorization &<br>Quantity Limits |
| 4/1/2024          | PENBRAYA 0.5ML INJECTION         |  | Addition to<br>Formulary | General<br>Formulary<br>Maintenance | Drug is on Tier 3   |
| 4/1/2024          |                                  | risperidone er 12.5mg injection            | Addition to<br>Formulary | General<br>Formulary<br>Maintenance | Drug is on Tier 4<br>with Step Therapy                                |

(Updated 5/1/2024)

# Changes made to the drugs in Medicare Plus Blue Group PPO and Prescription Blue Group PDP Group Comprehensive and Group Enhanced Comprehensive Formularies (additions, deletions, changes in coverage)

| Effective<br>Date | Brand Name  | Generic Name  | Type of<br>Change        | Reason for<br>Change                | Notes   |
|-------------------|---|---|--------------------------|-------------------------------------|---|
| 4/1/2024          |   | risperidone er 25mg, 37.5mg,<br>50mg injection  | Addition to<br>Formulary | General<br>Formulary<br>Maintenance | Drug is on Tier 5<br>with Step Therapy                                |
| 4/1/2024          |   | sodium sulfate/potassium<br>sulfate/magnesium sulfate<br>1.6gm/177ml; 3.13gm/177ml;<br>17.5gm/177ml oral solution | Addition to<br>Formulary | General<br>Formulary<br>Maintenance | Drug is on Tier 4   |
| 4/1/2024          | SYNJARDY XR 5MG/1000MG,<br>10MG/1000MG, 12.5MG/1000MG,<br>25MG/1000MG EXTENDED-RELEASE ORAL<br>TABLET |   | Addition to<br>Formulary | General<br>Formulary<br>Maintenance | Drug is on Tier 3<br>with Quantity Limits                             |
| 4/1/2024          | XALKORI 20MG, 50MG, 150MG ORAL<br>CAPSULE SPRINKL/E   |   | Addition to<br>Formulary | General<br>Formulary<br>Maintenance | Drug is on Tier 5<br>with Prior<br>Authorization &<br>Quantity Limits |

(Updated 5/1/2024)

# Changes made to the drugs in Medicare Plus Blue Group PPO and Prescription Blue Group PDP Group Comprehensive and Group Enhanced Comprehensive Formularies (additions, deletions, changes in coverage)

| Effective<br>Date | Brand Name   | Generic Name | Type of<br>Change        | Reason for<br>Change                | Notes   |
|-------------------|--|--------------|--------------------------|-------------------------------------|---|
| 4/1/2024          | ZILBRYSQ 23MG/0.574ML,<br>32.4MG/0.81ML PREFILLED SYRINGE<br>INJECTION |              | Addition to<br>Formulary | General<br>Formulary<br>Maintenance | Drug is on Tier 5<br>with Prior<br>Authorization &<br>Quantity Limits |

(Updated 5/1/2024)

## Changes made to the drugs in Medicare Plus Blue Group PPO and Prescription Blue Group PDP Group Comprehensive and Group Enhanced Comprehensive Formularies (additions, deletions, changes in coverage)

| Effective<br>Date | Brand Name                                    | Generic Name  | Type of<br>Change        | Reason for<br>Change                | Notes   |
|-------------------|---|---|--------------------------|-------------------------------------|---|
| 3/1/2024          | AKEEGA 500MG/50MG, 500MG/100MG<br>ORAL TABLET |   | Addition to<br>Formulary | General<br>Formulary<br>Maintenance | Drug is on Tier 5<br>with Prior<br>Authorization &<br>Quantity Limits |
| 3/1/2024          | AUGTYRO 40MG ORAL CAPSULE                     |   | Addition to<br>Formulary | General<br>Formulary<br>Maintenance | Drug is on Tier 5<br>with Prior<br>Authorization &<br>Quantity Limits |
| 3/1/2024          |   | ethinyl estradiol/norelgestromin<br>35mcg/24hr; 150mcg/24hr<br>transdermal system | Addition to<br>Formulary | General<br>Formulary<br>Maintenance | Drug is on Tier 2   |
| 3/1/2024          | KALYDECO 5.8 MG ORAL GRANULES                 |   | Addition to<br>Formulary | General<br>Formulary<br>Maintenance | Drug is on Tier 5<br>with Prior<br>Authorization                      |
| 3/1/2024          | OGSIVEO 50MG ORAL TABLET                      |   | Addition to<br>Formulary | General<br>Formulary<br>Maintenance | Drug is on Tier 5<br>with Prior<br>Authorization &<br>Quantity Limits |

(Updated 5/1/2024)

## Changes made to the drugs in Medicare Plus Blue Group PPO and Prescription Blue Group PDP Group Comprehensive and Group Enhanced Comprehensive Formularies (additions, deletions, changes in coverage)

| Effective<br>Date | Brand Name  | Generic Name | Type of<br>Change        | Reason for<br>Change                | Notes             |
|-------------------|---|--------------|--------------------------|-------------------------------------|-------------------|
| 3/1/2024          | ZENPEP 252,600/60,000/189,600 UNITS<br>DELAYED RELEASE ORAL CAPSULE |              | Addition to<br>Formulary | General<br>Formulary<br>Maintenance | Drug is on Tier 3 |

(Updated 5/1/2024)

# Changes made to the drugs in Medicare Plus Blue Group PPO and Prescription Blue Group PDP Group Comprehensive and Group Enhanced Comprehensive Formularies (additions, deletions, changes in coverage)

| Effective<br>Date | Brand Name   | Generic Name   | Type of<br>Change        | Reason for<br>Change                | Notes   |
|-------------------|--|--|--------------------------|-------------------------------------|---|
| 2/1/2024          | BREO ELLIPTA 50MCG/INH; 25MCG/INH<br>AEROSOL POWDER BREATH ACTIVATED |  | Addition to<br>Formulary | General<br>Formulary<br>Maintenance | Drug is on Tier 3 with Quantity Limits                                |
| 2/1/2024          |  | brimonidine tartrate 0.1% ophthalmic solution        | Addition to<br>Formulary | General<br>Formulary<br>Maintenance | Drug is on Tier 3   |
| 2/1/2024          |  | enilloring 0.015mg/24hr;<br>0.12mg/24hr vaginal ring | Addition to<br>Formulary | General<br>Formulary<br>Maintenance | Drug is on Tier 4   |
| 2/1/2024          | FRUZAQLA 1MG, 5MG ORAL CAPSULE                                       |  | Addition to<br>Formulary | General<br>Formulary<br>Maintenance | Drug is on Tier 5<br>with Prior<br>Authorization &<br>Quantity Limits |
| 2/1/2024          |  | glipizide 2.5mg oral tablet                          | Addition to<br>Formulary | General<br>Formulary<br>Maintenance | Drug is on Tier 2<br>with Quantity Limits                             |

(Updated 5/1/2024)

# Changes made to the drugs in Medicare Plus Blue Group PPO and Prescription Blue Group PDP Group Comprehensive and Group Enhanced Comprehensive Formularies (additions, deletions, changes in coverage)

| Effective<br>Date | Brand Name                  | Generic Name  | Type of<br>Change        | Reason for<br>Change                | Notes  |
|-------------------|-----------------------------|---|--------------------------|-------------------------------------|--|
| 2/1/2024          |                             | kourzeq 0.1% dental paste   | Addition to<br>Formulary | General<br>Formulary<br>Maintenance | Drug is on Tier 2                                |
| 2/1/2024          | LAGEVRIO 200MG ORAL CAPSULE |   | Addition to<br>Formulary | General<br>Formulary<br>Maintenance | Drug is on Tier 3 with Quantity Limits           |
| 2/1/2024          |                             | lisdexamfetamine dimesylate<br>10mg, 20mg, 30mg, 40mg,<br>50mg, 60mg, 70mg oral capsule | Addition to<br>Formulary | General<br>Formulary<br>Maintenance | Drug is on Tier 4<br>with Prior<br>Authorization |
| 2/1/2024          |                             | lithium 8meq/5ml oral solution  | Addition to<br>Formulary | General<br>Formulary<br>Maintenance | Drug is on Tier 2                                |
| 2/1/2024          | NUVESSA 1.3% VAGINAL GEL    |   | Addition to<br>Formulary | General<br>Formulary<br>Maintenance | Drug is on Tier 4                                |

(Updated 5/1/2024)

# Changes made to the drugs in Medicare Plus Blue Group PPO and Prescription Blue Group PDP Group Comprehensive and Group Enhanced Comprehensive Formularies (additions, deletions, changes in coverage)

| Effective<br>Date | Brand Name                                 | Generic Name                                 | Type of<br>Change        | Reason for<br>Change                | Notes   |
|-------------------|--|--|--------------------------|-------------------------------------|---|
| 2/1/2024          | OJJAARA 100MG, 150MG, 200MG ORAL<br>TABLET |  | Addition to<br>Formulary | General<br>Formulary<br>Maintenance | Drug is on Tier 5<br>with Prior<br>Authorization &<br>Quantity Limits |
| 2/1/2024          | OPVEE 2.7MG/0.1ML NASAL SPRAY              |  | Addition to<br>Formulary | General<br>Formulary<br>Maintenance | Drug is on Tier 3 with Quantity Limits                                |
| 2/1/2024          | PAXLOVID 150MG; 100MG ORAL TABLET<br>PACK  |  | Addition to<br>Formulary | General<br>Formulary<br>Maintenance | Drug is on Tier 3 with Quantity Limits                                |
| 2/1/2024          |  | pazopanib hydrochloride 200mg<br>oral tablet | Addition to<br>Formulary | General<br>Formulary<br>Maintenance | Drug is on Tier 5<br>with Prior<br>Authorization                      |
| 2/1/2024          |  | phenytek 200mg, 300mg oral capsule           | Addition to<br>Formulary | General<br>Formulary<br>Maintenance | Drug is on Tier 2   |

(Updated 5/1/2024)

# Changes made to the drugs in Medicare Plus Blue Group PPO and Prescription Blue Group PDP Group Comprehensive and Group Enhanced Comprehensive Formularies (additions, deletions, changes in coverage)

| Effective<br>Date | Brand Name   | Generic Name                                      | Type of<br>Change        | Reason for<br>Change                | Notes   |
|-------------------|--|---|--------------------------|-------------------------------------|---|
| 2/1/2024          |  | pitavastatin calcium 1mg, 2mg,<br>4mg oral tablet | Addition to<br>Formulary | General<br>Formulary<br>Maintenance | Drug is on Tier 1 with Quantity Limits                                |
| 2/1/2024          | SOHONOS 1MG, 1.5MG, 2.5MG, 5MG,<br>10MG ORAL CAPSULE |   | Addition to<br>Formulary | General<br>Formulary<br>Maintenance | Drug is on Tier 5<br>with Prior<br>Authorization &<br>Quantity Limits |
| 2/1/2024          | TRUQAP 160MG, 200MG ORAL TABLET                      |   | Addition to<br>Formulary | General<br>Formulary<br>Maintenance | Drug is on Tier 5<br>with Prior<br>Authorization &<br>Quantity Limits |
| 2/1/2024          |  | turqoz 30mcg; 0.3mg oral tablet                   | Addition to<br>Formulary | General<br>Formulary<br>Maintenance | Drug is on Tier 2   |
| 2/1/2024          | VANFLYTA 17.7MG, 26.5MG ORAL<br>TABLET               |   | Addition to<br>Formulary | General<br>Formulary<br>Maintenance | Drug is on Tier 5<br>with Prior<br>Authorization &<br>Quantity Limits |

(Updated 5/1/2024)

# Changes made to the drugs in Medicare Plus Blue Group PPO and Prescription Blue Group PDP Group Comprehensive and Group Enhanced Comprehensive Formularies (additions, deletions, changes in coverage)

| Effective<br>Date | Brand Name                                | Generic Name  | Type of<br>Change        | Reason for<br>Change                | Notes   |
|-------------------|---|---|--------------------------|-------------------------------------|---|
| 2/1/2024          | XDEMVY 0.25% OPHTHALMIC SOLUTION          |   | Addition to<br>Formulary | General<br>Formulary<br>Maintenance | Drug is on Tier 5<br>with Prior<br>Authorization &<br>Quantity Limits |
| 2/1/2024          | ZURZUVAE 20MG, 25MG, 30MG ORAL<br>CAPSULE |   | Addition to<br>Formulary | General<br>Formulary<br>Maintenance | Drug is on Tier 5<br>with Prior<br>Authorization &<br>Quantity Limits |
| 2/1/2024          |   | budesonide 0.25mg/2ml,<br>0.5mg/2ml, 1mg/2ml inhalation<br>suspension | Tier Decrease            | General<br>Formulary<br>Maintenance | Drug is on Tier 3<br>with BvsD Prior<br>Authorization                 |